VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

Weight loss jabs could reduce the risk of up to 14 types of cancer, new research has found. Mounjaro, Ozempic and other ...

Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

FROM sulphur burps to diarrhoea and nausea, there are many widely known Ozempic side effects – but there’s also a whole host of nasty long-term issues experts are only just uncovering.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Weight loss jabs combined with lifestyle choices can be a gamechanger for those stuck in the cycle of yo-yo-dieting.

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

Adults with obesity using a GLP-1 have a similar risk for obesity-related cancers as those who undergo bariatric surgery, ...